Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 12376 - 12400 of 12882 in total

OTL-102

OTL-102 consists of autologous CD34+ enriched cells that contain hematopoietic stem and progenitor cells transduced ex vivo using a lentiviral vector encoding the human gp91phox gene. It is being investigated for the treatment of X-linked chronic granulomatous disease.
Investigational

AVR-RD-04

AVR-RD-04 is an investigational gene therapy for cystinosis. It consists of autologous CD34+ enriched cells transduced with a lentiviral vector containing RNA resulting in codon-optimized cDNA encoding for functional human cystinosin.
Investigational

EDIT-301

EDIT-301 is an investigational cell therapy consisting of autologous CD34+ hematopoietic stem and progenitor cells edited by CRISPR/CAS12a at the gamma globin gene (HBG1 and HBG2).
Investigational

SLN124

SLN124 is a synthetic double-stranded siRNA oligonucleotide directed against TMPRSS6 mRNA and covalently linked to a ligand containing 3 N-acetylgalactosamine residues.
Investigational

Allogenic fetal mesenchymal stem cells

Investigational

HUB-101

Investigational

AMP-201

AMP-201 comprises an adeno-associated virus type 8 vector (AAV8) encoding the collagen Q gene (COLQ). It is under investigation for the treatment of collagen Q congenital myasthenia.
Investigational

BGT-DTDS

BGT-DTDS is an investigational gene therapy comprising an adeno-associated viral vector type 2 (AAV2) encoding the human SLC6A3 gene. It is under investigation for the treatment of dopamine transporter deficiency syndrome (DTDS).
Investigational

RGG0853

RGG0853 is an E1A lipid complex, a repressor gene complexed with a cationic lipid vector.
Investigational

Suratadenoturev

Suratadenoturev is a gene-modified oncolytic adenovirus expressing the telomerase reverse transcriptase gene.
Investigational

Ozekibart

Ozekibart is a tetravalent recombinant humanized IgG1 agonist antibody targeting the human TRAIL death receptor 5 (DR5). It is being investigated for the treatment of chondrosarcoma.
Investigational

MBP134

MBP134 is a pan-ebolavirus cocktail comprising two broadly neutralizing human antibodies. It is under investigation for the treatment of Sudan ebolavirus (SUDV).
Investigational

EDIT-101

EDIT-101 is a recombinant adeno-associated virus pseudotyped with serotype 5 viral capsid encoding CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats associated protein 9) gene editing constructs.
Investigational

Cellspan Esophageal Implant

The Cellspan Esophageal ImplantTM (CEI) composes of autologous adipose-derived mesenchymal stromal cells (Ad-MSC) seeded onto a polyurethane tubular mesh cell delivery device.
Investigational

TZ-101

TZ-101 composes of GDP-L-fucose and fucosyltransferase VI
Investigational

inBreath airway transplant system

inBreath airway transplant system composes of a scaffold seeded with autologous bone marrow cells and incubated in the bioreactor for two days prior to implant.
Investigational

ISA101b

ISA101b (peltopepimut-S) is a therapeutic vaccine against the HPV-specific E6/E7 oncoproteins.
Investigational

ABBV-706

ABBV-706 is an antibody-drug conjugate that is anti-SEZ6.[L49156,L49161]
Investigational

Tulisokibart

PRA023 is a humanized monoclonal antibody directed to vascular endothelial growth inhibitor, also known as tumour necrosis factor (TNF)-like ligand 1A (TL1A) and TNF superfamily member 15. It is being investigated for ulcerative colitis.
Investigational

CN-201

CN-201 is a humanized anti-CD3/CD19 bispecific antibody.
Investigational

HH-009

HH-009 is a recombinant human IgG4 monoclonal antibody against FGF19 being studied for the treatment of hepatocellular carcinoma.
Investigational

HTPEP-001

HTPEP-001 is a novel peptide that works to inhibit the activation of transforming growth factor beta (TGF-β). It is being investigated for the treatment of fibrosis.
Investigational

Sacituzumab tirumotecan

Sacituzumab tirumotecan is a recombinant humanized IgG1 anti-TROP2 monoclonal antibody conjugated to a topoisomerase I inhibitor.
Investigational

Tidutamab

Tidutamab is under investigation in clinical trial NCT04590781 (Safety and Efficacy of Xmab18087 ± Pembrolizumab in Advanced Merkel Cell Carcinoma or Extensive-stage Small Cell Lung Cancer).
Investigational

Domvanalimab

Domvanalimab is under investigation in clinical trial NCT05502237 (Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-small Cell Lung Cancer).
Investigational
Displaying drugs 12376 - 12400 of 12882 in total